Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and …
ZE Barter, MK Bayliss, PH Beaune… - Current drug …, 2007 - ingentaconnect.com
Reported predictions of human in vivo hepatic clearance from in vitro data have used a variety
of values for the scaling factors human microsomal protein (MPPGL) and hepatocellularity …
of values for the scaling factors human microsomal protein (MPPGL) and hepatocellularity …
Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling
ZE Barter, JE Chowdry, JR Harlow, JE Snawder… - Drug Metabolism and …, 2008 - ASPET
Scaling of metabolic clearance values from liver microsomal data or recombinantly expressed
cytochrome P450 enzymes to predict human hepatic clearance requires knowledge of the …
cytochrome P450 enzymes to predict human hepatic clearance requires knowledge of the …
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based …
…, EM Howgate, A Rostami-Hodjegan, ZE Barter - Xenobiotica, 2011 - Taylor & Francis
Prediction of metabolic clearance in extreme individuals rather than the ‘average human’ is
becoming an attractive tool within the pharmaceutical industry. The current study involved …
becoming an attractive tool within the pharmaceutical industry. The current study involved …
Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based …
ZE Barter, GT Tucker, K Rowland-Yeo - Clinical pharmacokinetics, 2013 - Springer
Background International Conference on Harmonization of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for better …
Registration of Pharmaceuticals for Human Use (ICH) guidelines emphasize the need for better …
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug–drug interactions
F Salem, TN Johnson, ZE Barter… - The Journal of …, 2013 - Wiley Online Library
The magnitude of any metabolic drug–drug interactions (DDIs) depends on fractional
importance of inhibited pathway which may not necessarily be the same in young children when …
importance of inhibited pathway which may not necessarily be the same in young children when …
Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic …
HK Crewe, ZE Barter, K Rowland Yeo… - … & drug disposition, 2011 - Wiley Online Library
The ‘relative activity factor’ (RAF) compares the activity per unit of microsomal protein in
recombinantly expressed cytochrome P450 enzymes (rhCYP) and human liver without …
recombinantly expressed cytochrome P450 enzymes (rhCYP) and human liver without …
Determination of a quantitative relationship between hepatic CYP3A5* 1/* 3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual …
ZE Barter, HF Perrett, KR Yeo, D Allorge… - … & drug disposition, 2010 - Wiley Online Library
The creation of virtual populations allows the estimation of pharmacokinetic parameters, such
as metabolic clearance in extreme individuals rather than the ‘average human’. Prediction …
as metabolic clearance in extreme individuals rather than the ‘average human’. Prediction …
Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes
HF Perrett, ZE Barter, BC Jones, H Yamazaki… - Drug metabolism and …, 2007 - ASPET
An analysis of reported hepatic abundances of CYP3A4 and 3A5 indicated that values
determined by immunoquantification using commercially available, unpurified recombinant …
determined by immunoquantification using commercially available, unpurified recombinant …
Response to “Ethnic-Specific In Vitro–In Vivo Extrapolation and Physiologically Based Pharmacokinetic Approaches to Predict Cytochrome P450-Mediated …
ZE Barter, GT Tucker, K Rowland-Yeo - Clinical pharmacokinetics, 2014 - Springer
We thank Dr Li and his colleagues for their comments, and agree that the development of
population physiologically based pharmacokinetic models is always a work in progress …
population physiologically based pharmacokinetic models is always a work in progress …
A meta-analysis of CYP3A4 abudance in human liver: Use of different standards contributes to apparent heterogeneity in reported values
ZE Barter, K Rowland Yeo, GT Tucker… - JOURNAL OF …, 2006 - certara.com
A META-ANALYSIS OF CYP3A4 ABUNDANCE IN HUMAN LIVER: USE OF DIFFERENT
STANDARDS CONTRIBUTES TO APPARENT HETEROGENEITY IN REPORTED Page 1 A …
STANDARDS CONTRIBUTES TO APPARENT HETEROGENEITY IN REPORTED Page 1 A …